Amneal Pharmaceuticals Inc (Amneal)(Nasdaq: AMRX), an integrated pharmaceutical company, announced on Friday the appointment of David A. Buchen to the newly expanded role of senior vice president, chief legal officer and corporate secretary.
In his new role, Buchen will report to president and CEO Robert Stewart. Buchen will be responsible for leading Amneal's global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company's corporate legal strategies to drive Amneal's continued growth.
Also, to ensure a smooth leadership transition, Amneal's senior vice president, general counsel, Sheldon Hirt, will remain on board through January 2019 before leaving the company to pursue other opportunities.
Most recently, Buchen served as a consultant to the pharmaceutical industry, providing counsel to various global and US manufacturing, marketing and distribution companies. Prior to establishing his consultancy, he held several executive leadership roles, including serving as EVP – Commercial, North American Generics and International, as well as 12 years as chief legal officer and corporate secretary at Watson Pharmaceuticals (rebranded as Actavis plc).
Amneal Pharmaceuticals is focused on developing, manufacturing and distributing generic, brand and biosimilar products.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical